Insurer Accuses Jazz Pharma Of 'Grotesque' Antitrust Scheme

By J. Edward Moreno (October 12, 2021, 5:49 PM EDT) -- A California health care provider accused Jazz Pharmaceuticals of conspiring with competitors to delay generic versions of its Xyrem narcolepsy drug and of instituting "grotesque" price hikes.

In a complaint filed Friday, Molina Healthcare said Jazz abused the Federal Drug Administration's Risk Evaluation and Mitigation Strategy program, or REMS, filed "sham patent" lawsuits and entered into agreements with its competitors to delay the rollout of generic versions of Xyrem.

"All the while, Jazz imposed a series of grotesque price hikes that would have been impossible had generic entry been successful," Molina said, adding that the scheme caused it to pay inflated...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!